ClinicalTrials.gg
Active, not recruitingNCT06175351Updated May 20, 2025

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

A Phase 1/2 interventional study of 9MW1911 and Placebo in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Active, not recruiting at 22 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.
  • Registered 4 months after the study started (first participant enrolled Jul 2023, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
190th of 286
80 · median 155
Started
2023
with 44 others
Phase 1/2
6 of 404
2 open now
Primary completion
2025-09
later than 25 of 124 live
Registered
281st of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 190th largest by planned enrollment of the 286 interventional ones that give a count, is one of 45 that started in 2023, is one of 6 in phase 1/2, reaches primary completion later than 25 of the 124 other live ones, and was the 281st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The study will evaluate the pharmacokinetic characteristics, safety, tolerability, and preliminary efficacy of 9MW1911 in combination with standard of care COPD maintenance therapy in patients with moderate to severe COPD.

03

Conditions studied

  • Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients must be >=40 years of age and capable of giving signed .
  2. (BMI) of 16 kg/m² to 32 kg/m².
  3. Documented physician diagnosis of for at least 1 year.
  4. Smoking history with a minimum of 10 pack-year.
  5. Post-bronchodilator of >=30 and \<80% of predicted normal value at screening.
  6. Modified Medical Research Council (dyspnea scale) (mMRC) score>=2.
  7. COPD assessment score (CAT) score >=10, with each of the phlegm and cough items with a score >=2.
  8. Documented stable, standard-of-care COPD maintenance therapy for at least 8 weeks prior to screening, with no anticipated changes during the screening period and throughout the study.
  9. Documented history of >= 2 moderate or >=1 severe COPD exacerbations within 12 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines, or documented history of asthma.
  2. Diagnosis of Alpha-1 Antitrypsin Deficiency.
  3. Moderate to severe exacerbation, within 4 weeks prior to randomization.
  4. History of lung pneumonectomy, or lung volume reduction within 12 months prior to screening.
  5. respiratory disease other than COPD that significantly affect the study.
  6. Evidence of active injection with Mycobacterium tuberculosis or nontuberculous mycobacteria, latent, or inadequately treated infection with Mycobacterium tuberculosis.
  7. COVID-19 vaccination injection within 14 days before randomization.
  8. Long-term treatment with oxygen (oxygen therapy time >15h/day), or treatment with mechanical ventilation
  9. Clinically significant sleep apnea requiring continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV).
  10. Participating in, or scheduled for a pulmonary rehabilitation program within 4 weeks of screening.
  11. Clinically significant abnormal (ECG) at randomization that may affect the conduct of the study.
  12. Myocardial infarction, unstable angina, or stroke occurring within 12 months prior to screening;
  13. Heart failure ( Class III or IV) within 6 months prior to screening.
  14. Uncontrolled hypertension (ie, systolic blood pressure>180 mmHg or diastolic blood pressure >110 mmHg with or without use of anti-hypertensive therapy).
  15. Treatment with other biological agents (including anti-IL4, IL-5, IL-13 monoclonal antibodies) or therapy within 2 months prior to screening.
  16. Alcohol or drug abuse within 1 year prior to screening.
  17. , current or within the past 5 years. Suspected malignancy or undefined neoplasms.
  18. Positive test for surface antigen (HbsAg), virus antibody (HCVAb), Syphilis Treponema pallidum antibody (Syphilis TP), or (HIV Ag/Ab).
  19. (ALT) >= 2 times the (ULN); Aspartate aminotransferase (AST) >= 2 times ULN; Total >= 1.5 times ULN.
  20. Estimated (eGFR) \<60 mL/min/1.73m2.
  21. History of systemic allergic reaction (including systemic allergic reaction to any biological therapy), or history of immediate allergic reaction to any biological therapy.
  22. Participation in an interventional clinical studies within 3 months that could affect the result of this study.
  23. Pregnant or lactating women. Women of (WOCBP) with a positive blood serum pregnancy test at screening. Planning a pregnancy during the intervention period and for at least 20 weeks after the last dose of study intervention. Subjects of child-bearing potential (including female subjects, male subjects and their female partners of child-bearing potential) unable to use reliable during the intervention period and for at least 20 weeks after the last dose of study intervention.
  24. Confirmed COVID-19 infection at screening. Known history of COVID-19 infection within 4 weeks prior to screening. History of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to screening. Participants who have had a COVID-19 infection prior screening have not yet sufficiently recovered to participate in the procedures of a clinical trial.
  25. of no more than 12 months.
  26. Subjects who is inappropriate to participate in the trial due to any reasons as determined by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Phase Ib 9MW1911

    9MW1911 is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 6 patients.

    Drug: 9MW1911

  • Experimental
    Phase IIa 9MW1911

    9MW1911 is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 18 patients.

    Drug: 9MW1911

  • Placebo comparator
    Phase Ib Placebo

    Placebo is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 2 patients.

    Drug: Placebo

  • Placebo comparator
    Phase IIa Placebo

    Placebo is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 6 patients.

    Drug: Placebo

Interventions

  • Drug9MW1911

    Participants will receive IV 9MW1911 every 4 weeks.

  • DrugPlacebo

    Participants will receive IV placebo every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic characteristics.

    Peak concentration (Cmax)

    Time frame: 36 weeks

  2. Pharmacokinetic characteristics.

    Time to peak concentration (Tmax)

    Time frame: 36 weeks

  3. Pharmacokinetic characteristics.

    Area under the drug concentration-time curve from time zero to the last measurable concentration time (AUC0-t)

    Time frame: 36 weeks

  4. Pharmacokinetic characteristics.

    Elimination half-life (t1/2)

    Time frame: 36 weeks

  5. Pharmacokinetic characteristics.

    Accumulation ratio based on AUC (Rac (AUC))

    Time frame: 36 weeks

  6. Pharmacokinetic characteristics.

    Accumulation ratio based on peak concentration (Rac (Cmax))

    Time frame: 36 weeks

  7. Safety and tolerability

    The incidence of AEs (adverse events) and SAEs (serious adverse events) from treatment until the last scheduled follow-up visit

    Time frame: 36 weeks

Secondary outcomes

  1. Changes from baseline in pre-bronchodilator FEV1 (forced expiratory volume at one second).

    Changes in pre-bronchodilator FEV1 levels at 4, 8, 12, and 24 weeks compared to baseline.

    Time frame: Weeks 0, 4, 8, 12, 24

  2. Changes from baseline in post-bronchodilator FEV1.

    Changes in post-bronchodilator FEV1 levels at 4, 8, 12, and 24 weeks compared to baseline.

    Time frame: Weeks 0, 4, 8, 12, 24

  3. Changes from baseline in post-brochodilator FEV1(%pred).

    Changes in post-brochodilator FEV1(%pred) levels at 4, 8, 12, and 24 weeks compared to baseline.

    Time frame: Weeks 0, 4, 8, 12, 24

  4. Time to first moderate to severe Chronic Obstructive Pulmonary Disease Acute Exacerbation (AECOPD) from baseline to week 24.

    Time to first moderate to severe Chronic Obstructive Pulmonary Disease Acute Exacerbation (AECOPD) from baseline to week 24.

    Time frame: Baseline to week 24.

  5. Annualized rate of moderate to severe AECOPD over the 24-week treatment period.

    Time frame: 24 weeks

  6. Changes from baseline in mMRC(Modified Medical Research Council) dyspnea scale at 12 and 24 weeks.

    Changes in mMRC dyspnea scale at 12 and 24 weeks compared to baseline.

    Time frame: Weeks 0, 12, 24

  7. Changes from baseline in CAT(COPD Assessment Test) score at 12 and 24 weeks.

    Changes in CAT score at 12 and 24 weeks compared to baseline.

    Time frame: Weeks 0, 12, 24

  8. Incidence of ADAs Against 9MW1911.

    The incidence of ADAs against 9MW1911 during the study will be summarized.

    Time frame: 36 weeks

07

Study locations

22 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Sep 2025, 26 months after the start.

Of 21 phase 1/2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 18, 2023
StartActual
Jul 6, 2023
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06175351
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jul 6, 2023
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
May 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion